Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

Post-neoadjuvant escalation after residual disease

Ask about this lesson

In one sentence

Post-neoadjuvant escalation adds or changes treatment after surgery when cancer remains in the surgical specimen after preoperative therapy, using options whose evidence ranges from randomized proof to ongoing trials.

The intuition

Preoperative treatment is a test run as well as a treatment. If surgery finds no invasive cancer (pathologic complete response, pCR), the outlook is better. If cancer remains, the risk of recurrence is higher, and the remaining cells have shown some resistance. Escalation means trying something different or additional for that higher-risk group. The analogy has a limit: knowing risk is higher does not tell you which added drug lowers it. Only comparisons do.

How it works

In triple-negative breast cancer (TNBC), surgery after preoperative therapy sorts people into pCR and residual disease. Most options below were tested in human epidermal growth factor receptor 2 (HER2)-negative or triple-negative disease. Each added option was tested in a defined group, after a defined earlier treatment. Read them as rungs on an evidence ladder.

RungOption and trialWho was studiedWhat it showed
Randomized, practice-establishingContinue pembrolizumab for up to 9 cycles (KEYNOTE-522)Stage II–III TNBC; given after surgery whatever the pathology showedPart of a strategy that improved event-free and overall survival [1]
Randomized, practice-establishingCapecitabine (CREATE-X)910 people with HER2-negative residual invasive cancer after anthracycline or taxane chemotherapyTNBC subgroup: 5-year disease-free survival 69.8% vs 56.1% (hazard ratio, HR, 0.58); overall survival 78.8% vs 70.3% (HR 0.52) [2]
Randomized, practice-establishingOlaparib for 1 year (OlympiA)1,836 people with a germline BRCA1 or BRCA2 variant and high-risk HER2-negative disease3-year invasive disease-free survival 85.9% vs 77.1% (HR 0.58) [3]; 6-year overall survival 87.5% vs 83.2% (HR 0.72) [4]
Randomized, not betterPlatinum instead of capecitabine (EA1131)410 people with ≥1 cm residual TNBCBasal subtype: 3-year invasive disease-free survival 42% vs 49%; more severe toxicity; stopped early [5]
Randomized, not betterDrug matched to tumor sequencing (BRE12-158)193 people with residual TNBC2-year disease-free survival 56.6% vs 62.4% with physician's choice; no difference [6]
Untested combinationCapecitabine or olaparib added to postoperative pembrolizumab—CREATE-X and OlympiA predate checkpoint inhibitors; no randomized result yet
Ongoing phase 3Antibody-drug conjugates (ADCs): SASCIA, TROPION-Breast03, ASCENT-05/OptimICE-RDResidual disease after preoperative therapyRegistry records only; no efficacy results [7–9]

The gaps between rungs matter: higher risk ≠ a proven added drug ≠ proof that the drug helps after a different earlier regimen.

The ongoing ADC trials

All three use invasive disease-free survival as the primary endpoint.

  • SASCIA (NCT04595565): sacituzumab govitecan versus physician's choice of capecitabine, platinum or observation, in HER2-negative residual disease at high risk.
  • TROPION-Breast03 (NCT05629585): datopotamab deruxtecan with or without durvalumab versus investigator's choice, which may include capecitabine, pembrolizumab or both, in residual TNBC.
  • ASCENT-05/OptimICE-RD (NCT05633654): sacituzumab govitecan plus pembrolizumab versus pembrolizumab with or without capecitabine, in residual TNBC.

The control arms in the last two include pembrolizumab plus capecitabine. They compare against it; they do not test it.

What post-neoadjuvant blood tests have shown

Circulating tumor DNA (ctDNA) is tumor DNA in the blood; after treatment it is used to look for minimal residual disease. In BRE12-158, every participant already had residual disease. Within that group, detectable ctDNA was linked to worse distant disease-free survival (HR 2.99; 56% vs 81% at 24 months) [10]. So ctDNA was prognostic among people with residual disease. It was not shown to add beyond pCR, because there was no pCR group.

In c-TRAK TN, people with detected ctDNA were offered pembrolizumab. Of those allocated to treatment, 72% already had metastases on scans when ctDNA turned positive, and none of the 5 who started pembrolizumab cleared ctDNA durably [11]. No randomized trial has shown that acting on a ctDNA result improves survival.

Why it matters in cancer

  • Residual disease is common: in KEYNOTE-522, about 35 of every 100 people in the pembrolizumab arm (first 602 randomized) did not reach pCR [1]. Finding it is the main way preoperative treatment changes what happens after surgery.
  • Germline BRCA status decides whether olaparib is an option, so germline testing belongs before this decision.
  • Radiation after surgery is a separate local decision; see radiation basics.

Common confusions

  • "Residual disease" is not one category. Residual cancer burden (RCB) grades how much remains.
  • CREATE-X's TNBC result is a subgroup of a larger trial, in a population treated before immunotherapy. It is strong evidence, but not evidence about adding capecitabine to pembrolizumab.
  • A trial's eligibility for residual disease is not proof that its drug works.
  • A negative ctDNA test does not cancel residual tissue findings.

Try it

A fictional person had KEYNOTE-522 treatment, has residual TNBC and no germline BRCA variant. Which ladder rungs apply to her directly?

Answer: Continuing pembrolizumab is part of the tested strategy. Capecitabine has randomized evidence for residual TNBC, but not on top of pembrolizumab. Olaparib's evidence requires a germline BRCA variant, so it does not apply. ADC trials are ongoing and may be worth asking about.

Explain it back

"For residual TNBC, ___ is proven, ___ is extrapolated, and ___ is being tested."

One possible answer: "Continuing pembrolizumab, capecitabine alone and olaparib for germline BRCA carriers are proven in their populations; adding capecitabine or olaparib to pembrolizumab is extrapolated; ADCs are being tested."

Takeaway

After residual disease, name each option's rung: proven in its population, extrapolated to a new combination, or still in trials.

Sources and scope

Source-checked November 7, 2026 against primary abstracts and ClinicalTrials.gov records; registry searches found no efficacy results for the three ADC trials. Expert and learner review pending. General education, not a treatment recommendation.

References

  1. Schmid and colleagues, NEJM 2020 and 2024 — KEYNOTE-522 design, pCR and overall survival.
  2. Masuda and colleagues, NEJM 2017 — CREATE-X.
  3. Tutt and colleagues, NEJM 2021 — OlympiA primary analysis.
  4. OlympiA third interim analysis, Annals of Oncology 2026 — median follow-up 6.1 years.
  5. Mayer and colleagues, JCO 2021 — EA1131.
  6. Schneider and colleagues, JCO 2022 — BRE12-158.
  7. SASCIA, NCT04595565.
  8. TROPION-Breast03, NCT05629585.
  9. ASCENT-05/OptimICE-RD, NCT05633654.
  10. Radovich and colleagues, JAMA Oncology 2020 — preplanned secondary ctDNA analysis of BRE12-158.
  11. Turner and colleagues, Annals of Oncology 2023 — c-TRAK TN.

Used in